CD7 Expression in Acute Myeloid Leukemia

References

• Mayer R.J. Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin. Oncol. 1987; 14: 384–388
   PubMed Web of Science ®Google Scholar
• Mertelsmann R., Thaler H.T., To L., Gee T.S., McKenzie S., Schauer P., Friedman A., Arlin Z., Cirrincione C., Clarkson B. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 1980; 56: 773–781
   PubMed Web of Science ®Google Scholar
• Bloomfield C.D., Golman A., Hossfeld D., de la Chapelle A. The Fourth International Workshop on Chromosomes in Leukemia: The clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet. Cytogenet. 1984; 11: 332–338
   PubMedGoogle Scholar
• Griffin J.D., Davis R., Nelson D.A., Davey F.R., Mayer R.J., Schiffer C., McLntyre O.R., Bloomfield C.D. Use of surface marker analysis to predict outcome of adult myeloblasts leukemia. Stood 1986; 68: 1232–1241
   Google Scholar
• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton A.G., Gralnick H.R., Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukemia (AML-MO). Br. J. Haematol. 1991; 78: 325–329
   PubMed Web of Science ®Google Scholar
• Stasi R., Del Poeta G., Venditti A., Masi M., Stipa E., Dentamaro T., Cox C., Dallapiccola B., Papa G. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-MO). Stood 1994; 83: 1619–1625
   Google Scholar
• Terstappen L. W. M. M., Loken M.R. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal. Cell. Pathol. 1990; 2: 229–240
   PubMed Web of Science ®Google Scholar
• Terstappen L. W. M. M., Shah V.O., Civin C.I., Hurwitz C.A., Loken M.R. Multidimensional flow cytometry as a new approach for discrimination between normal and leukemic cells in peripheralblood and bone marrow. Progress in cytometry. BDIS. 1989; 4–29, Erebodegem
   Google Scholar
• Claxton D.F., Reading C.L., Nagarajan L., Tsujimoto Y., Anderssonn B.S., Estey E., Cork A., Huh Y.O., Trujillo J., Deisseroth A.B. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 1992; 80: 582–590
   PubMed Web of Science ®Google Scholar
• Vodinelich L., Tax L.V., Bay Y., Pegram S., Capel P., Greaves M.F. A monoclonal antibody (WT1) for detecting leukemias of T-cell precursors (T-ALL). Blood 1983; 62: 1108–1117
   PubMed Web of Science ®Google Scholar
• Greaves M.F., Chan L.C., Furley A. J. W., Watt S.M., Molgaard H.V. Lineage promiscuity in hematopoietic differentiation and leukemia. Blood 1986; 67: 1–13
   PubMed Web of Science ®Google Scholar
• Gale R.P., Bassat I.B. Hybrid acute leukemia. Br. J: Haematol 1987; 65: 261–70
   PubMed Web of Science ®Google Scholar
• Cross A.H., Goorha R.M., Nuss R., Behm F.G., Murphy S.B., Kalwinsky D.K., Raimondi S., Kitchingman G.R., Mirro J., Jr. Acute myeloid leukemia with T-lymphoid features: A distinct biologic and clinical entity. Blood 1988; 72: 579–587
   PubMed Web of Science ®Google Scholar
• Bradstock K.F., Kirk J., Grimsley P.G., Karbral A., Hughes W.G. Unusual immunophenotypes in acute leukemias: Incidence and clinical correlations. Br. J. Haematol. 1989; 72: 512–518
   PubMed Web of Science ®Google Scholar
• Ball E.D., Davis R.B., Griffin J.D., Mayer R.J., Davey F.R., Arthur D.C., Wurster-Hill D., Noll W., Elghetany T., Allen S.L., Rai K., Lee E.J., Schiffer C.A., Bloomfield C.D. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood 1991; 77: 2242–2250
   PubMed Web of Science ®Google Scholar
• Norton J.D., Campana D., Hoffbrand A.V., Janossy G., Coustan-Smith H., Jani H., Yaxley J.C., Prentice H.G. Rearrangement of immunoglobulin and T cell antigen receptor genes in acute myeloid leukemia with lymphoid-associated markers. Leukemia 1987; 1: 757–765
   PubMed Web of Science ®Google Scholar
• Jensen A.W., Hokland M., Jorgensen H., Justesen J., Ellegaard J., Hokland P. Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: identification of a group of patients with a similar T-cell receptor beta and delta rearrangements and course of disease suggestive of poor prognosis. Blood 1991; 78: 1292–1300
   PubMed Web of Science ®Google Scholar
• Chabannon C., Wood P., Torok-Storb B. Expression of CD7 on normal human myeloid progenitors. J. Immunol. 1992; 149: 2110–2113
   PubMed Web of Science ®Google Scholar
• Kurtzberg J., Waldmann T.A., Davey M.P., Bigner S.H., Moore J.O., Hershfield M.S., Haynes B.F. CD7+, CD4-, CD8-acute leukemia: a syndrome of malignant pluripotent lymphohematopietic cells. Blood 1989; 73: 381–390
   PubMed Web of Science ®Google Scholar
• Zittoun R., Liso V., Mandelli F., Rotoli B., de Witte T., Gattringer C., Resegotti L., Caronia F., Leoni P., Petti M.C., Solbu G., Vegna M.L., Suciu S. for the EORTC Leukemia Cooperative Group and the GIMEMA Group. Intensive consolidation chemotherapy vs. standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML 8B). Leukemia 1992; 6(suppl 2)76–77
   PubMedGoogle Scholar
• Zittoun R., Mandelli F., Willemze R., de Witte T., Tura S., Ferrini P.R., Stryckmans P., Gattringer C., Petti M.C., Solbu G., Vegna M.L., Suciu, S. for the EORTC Leukemia Cooperative Group and the GIMEMA Group. Allogeneic vs. autologous bone marrow transplantation vs. intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML 8A). Leukemia 1992; 6(suppl 2)114–115
   PubMedGoogle Scholar
• Resegotti, L. for the GIMEMA Group. Treatment of acute nonlymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience. Leukemia 1992; 6(suppl 2)72–75
   PubMedGoogle Scholar
• Avvisati G., Petti M.C., Spadea A., Lazzarino M., Alessandrino E.P., Liso V., Specchia G., Carella A.M., Falda M., Fioritoni G., Ladogana F., Mandelli F. for the cooperative group GIMEMA. Idarubicin (IDA) treatment in acute promyelocytic leukemia (APL): the GIMEMA experience. Haematologica 1991; 76(suppl 4)10
   PubMedGoogle Scholar
• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D. A. G., Gralnick H.R., Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Campos L., Guyotat D., Archimbaud E., Calmard-Oriol P., Tsuruo T., Troncy J., Treille D., Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473–476
   PubMed Web of Science ®Google Scholar
• Sladek T.L., Jacobberger J.W. Flow cytometric titration of retroviral expression vectors: Comparison of methods for analysis of immunofluorescence histograms derived from cells expressing low antigen levels. Cytometry 1993; 14: 23–31
   PubMedGoogle Scholar
• Overton W. Modified histogram subtraction technique for analysis of flow cytometry data. Cytometry 1988; 9: 619–626
   PubMedGoogle Scholar
• Stasi R., Tribalto M., Venditti A., Del Poeta G., Aronica G., Zaccari G., Rossi V., Maffei L., Papa G. Simultaneous occurence of monoclonal gammopathy and acute secondary leukemia with overexpression of P-glycoprotein. Tumori 1992; 78: 403–406
   PubMed Web of Science ®Google Scholar
• Stasi R., Del Poeta G., Masi M., Tribalto M., Venditti A., Papa G., Nicoletti B., Vernole P., Tedeschi B., Delaroche I., Mingarelli R., Dallapiccola B. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. Cancer Genet. Cytogenet. 1993; 67: 28–34
   PubMed Web of Science ®Google Scholar
• Kita K., Miwa H., Nakase K., Kawasami K., Kobayashi T., Shirakawa S., Tanaka I., Ohta C., Tsutani H., Oguma S., Kyo T., Dohy H., Kamada N., Nasu K., Uchino H. Clinical importance of CD7 expression in acute myelocytic leukemia. Blood 1993; 81: 2399–2405
   PubMed Web of Science ®Google Scholar
• Lo Coco F., De Rossi G., Pasqualetti D., Lopez M., Diverio D., Lalagliata R., Fenu S., Mandelli F. CD7 positive acute myeloid leukemia: A subtype associated with cell immaturity. Br. J. Haematol. 1989; 73: 480–485
   PubMed Web of Science ®Google Scholar
• Vidriales M.B., Orfao A., Gonzalez M., Hernandez G.M., Lopez-Berges M.C., Garcia M.A., Canizo M.C., Caballero M.D., Macedo A., Landolfi C., et al. Expression of NK and lymphoid associated antigens in blast cells of acute myeloblasts leukemia. Leukemia 1993; 7: 2026–2029
   PubMed Web of Science ®Google Scholar
• Drexler H.G., Thiel E., Ludwig W.D. Acute myeloid leukemias expressing lymphoid associated antigens: diagnostic incidence and prognostic significance. Leukemia 1993; 7: 489–498
   PubMed Web of Science ®Google Scholar
• Terstappen L. W. M. M., Safford M., Konemann S., Loken M.R., Zurlutter K., Buchner T., Hiddemann W., Wormann B. Flow Cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1991; 5: 757–767
   Web of Science ®Google Scholar
• Del Poeta G., Stasi R., Venditti A., Masi M., Papa G. CD7 expression in acute myeloid leukemia. Blood (letter) 1993; 82: 2929–2930
   PubMed Web of Science ®Google Scholar
• Del Poeta G., Stasi R., Venditti A., Suppo G., Aronica G., Bruno A., Masi M., Tabilio A., Papa G. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994; 8: 388–394
   PubMed Web of Science ®Google Scholar
• Bassan R., Biondi A., Benvestito S., Tini M.L., Abbate M., Viero P., Barbui T., Rambaldi A. Acute undifferentiated leukemia with CD7+ and CD 13+ immunophenotype. Lack of molecular lineage commitment and association with poor prognostic features. Cancer 1992; 69: 396–404
   PubMed Web of Science ®Google Scholar
• Geller R.B., Zahurak M., Craig A.H., Burke P.J., Karp J.E., Piantadosi S., Civin C.I. Prognostic importance of im-munophenotyping in adults with acute myelocytic leukemia: the significance of the stem cell glycoprotein CD34 (My 10). Br. J. Haematol. 1990; 76: 340–347
   PubMed Web of Science ®Google Scholar
• Zutter M.M., Martin P.J., Hanke D., Kidd P.G. CD7+ acute non-lymphocytic leukemia: evidence for an early multipotential progenitor. Leuk. Res. 1990; 14: 23–26
   PubMed Web of Science ®Google Scholar
• Sato H., Preisler H., Day R., Raza A., Larson R., Browman G., Goedberg J., Vogler R., Grunwold H., Gottlieb A., Bennett J., Gottesman M., Pastan I. MDR1 transcript levels as an indicator of resistant disease in acute myelogenous leukemia. Br. J. Haematol. 1990; 75: 340–345
   PubMed Web of Science ®Google Scholar
• Miwa H., Kita K., Nishii K., Morita N., Takakura N., Ohishi K., Mahmud N., Kageyama S., Fukumoto M., Shirakawa S. Expression of MDR1 gene in acute leukemia cells: Association with CD7+ acute myeloblastic/acute lymphoblastic leukemia. Blood 1993; 82: 3445–3451
   PubMed Web of Science ®Google Scholar